Plasmablastic Lymphoma clinical trials
The registry lists 18 studies for Plasmablastic Lymphoma across more than 10 countries. 11 are recruiting or about to start. 10 of them are mainly about Plasmablastic Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06.
Get an email when these change. Save the Plasmablastic Lymphoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (6) · AIDS Malignancy Consortium (3) · Fondazione Italiana Linfomi - ETS (2) · Xencor, Inc. (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jacob Soumerai, MD (1) · University of Illinois Chicago (1) · The First Affiliated Hospital with Nanjing Medical University (1)
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Jul 2027Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. · Fondazione Italiana Linfomi - ETS
- Aug 2027RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies · The First Affiliated Hospital with Nanjing Medical University
- Nov 2027Study of SGR-1505 in Mature B-Cell Neoplasms · Schrödinger, Inc.
Who these studies take
Of the 9 Plasmablastic Lymphoma studies recruiting now, 8 (89%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 9 (100%) | 9 (100%) |
| 50 | 9 (100%) | 9 (100%) |
| 65 | 9 (100%) | 9 (100%) |
| 75 | 9 (100%) | 9 (100%) |
| 85 | 9 (100%) | 9 (100%) |
Across all 18 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 6% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting2
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")Oct 28, 2026NCT07649304
- HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIVOct 26, 2026NCT07647432
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 18 of 18. search them.
- QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II StudyNot yet recruitingNCT07921615Phase 2
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")RecruitingNCT07649304Phase 11 country
- A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaRecruitingNCT04139304Early Phase 11 country
- HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIVRecruitingNCT07647432Phase 11 country
- Testing the Effect of Teclistamab on Recurrent Plasmablastic LymphomaRecruitingNCT07332507Phase 11 country
- Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.RecruitingNCT04915248Phase 21 country
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 11 country
- Study on Plasmablastic Lymphoma PatientsRecruitingNCT067813591 country
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related CancersRecruitingNCT056635021 country
- Study of SGR-1505 in Mature B-Cell NeoplasmsRecruitingNCT05544019Phase 18 countries
- RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic MalignanciesNot yet recruitingNCT07113496Phase 11 country
- Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasActive, not recruitingNCT03038672Phase 21 country
- Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell TransplantActive, not recruitingNCT02797470Phase 1/21 country
- Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell LymphomaTerminatedNCT04676360Phase 21 country
- Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesCompletedNCT02924402Phase 14 countries
- Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell LymphomasCompletedNCT01193842Phase 1/21 country
- Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell LymphomaCompletedNCT01092182Phase 21 country
- Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaStatus unknownNCT02481310Phase 1/21 country